Stability testing of tacrolimus-loaded poly(ԑ-caprolactone) nanoparticles by physicochemical assays and Raman spectroscopy

Camargo, Guilherme dos Anjos; Filha, Amanda Roderjan Cray da Costa; Lyra, Amanda Martinez; Novatski, Andressa; Nadal, Jéssica Mendes; Lara, Lucas Stori de; Dias, Daniele Toniolo; Nascimento, Elizangela Anazilda do; Silva, Uéslen Rocha; Jacinto, Carlos; Farago, Paulo Vítor

doi:10.1016/j.vibspec.2020.103139

Cited by 8 publications

(5 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this study, SV-loaded nanocapsules were successfully obtained as nanosuspensions by the interfacial deposition of preformed polymer. This formulation presented a final opalescent bluish aspect due to the Tyndall effect from colloids [23,25]. The mean particle size and PDI value were similar to those previously recorded by photon correlation spectroscopy for other polymeric nanocapsules [26].…”

Section: Discussionsupporting

confidence: 81%

“…PDI values close to zero are considered monodisperse and >0.5 indicate heterogeneous dispersion [23]. Zeta potential was also suitable since it was higher than |30 mV|, which is usually considered having sufficient repulsive force to achieve better physical colloidal stability [25]. The electron micrographs confirmed the spherical shape and the smooth surface, which are typical to polymeric nanocapsules, obtained using PCL as polymer [27].…”

Section: Discussionmentioning

confidence: 89%

See 1 more Smart Citation

Simvastatin-Loaded Nanocapsules Reduce TNF-Α Expression in Rat Peritoneum After Infusion of Peritoneal Dialysis Solution

Baroni

Ferronato

Camargo

et al. 2021

Asian J Pharm Clin Res

Self Cite

View full text Add to dashboard Cite

Objective: Obteinment and characterizing polymeric nanocapsules of simvastatin (SV), and investigating their action in an experimental model of peritoneal fibrosis induced in a rat by the infusion of peritoneal dialysis (PD) solution. Methods: Poly (ε-caprolactone) nanocapsules containing SV (NC-SV) were prepared by interfacial deposition of a preformed polymer. A suspension of nanoparticles with no drug was prepared as negative control. The average particle size and polydispersity index were measured by photon correlation spectroscopy. The morphological and surface evaluation of prepared nanocapsules was performed using field emission scanning electron microscopy. The ultra-high performance liquid chromatography with photodiode array detection method was used to evaluate the drug encapsulation efficiency. The release profiles of SV from polymeric nanocapsules were obtained by dialysis diffusion technique. The Animal Study was performed in a total of 48 male Wistar rats (Rattus norvegicus) divided in four groups: Sham, PD group, SV group, and Simvastatin-loaded nanocapsules group (NC-SV). After 28 days, tissue samples were surgically removed from the abdominal to perform histological and immunohistochemistry analysis. The statistical analysis was performed by one-way ANOVA followed by Bonferroni test, or by Kruskal–Wallis. Results: NC-SV presented suitable particle parameters with a mean particle size of 332 nm, and an encapsulation efficiency of 99.87±0.46%. The expression of tumor necrosis factor-alpha (TNF-α) was significantly different in NC-SV group. Conclusion: SV-loaded nanocapsules for controlled drug delivery were suitably prepared. This nanoformulation remarkable decreased the TNF-α tissue expression even at low SV dose in a chronic PD model.

show abstract

Section: Discussionsupporting

confidence: 81%

Section: Discussionmentioning

confidence: 89%

Simvastatin-Loaded Nanocapsules Reduce TNF-Α Expression in Rat Peritoneum After Infusion of Peritoneal Dialysis Solution

Baroni

Ferronato

Camargo

et al. 2021

Asian J Pharm Clin Res

Self Cite

View full text Add to dashboard Cite

show abstract

“…Regarding the preparation, the bluish opalescence observed for the nanoformulations is due to the brownian movement of polymeric nanoparticles known as the Tyndall effect as previously reported in the literature [16,26,27]. The eugenol concentration of 1.5 mg/mL was chosen because it is commonly used for formulations containing essential oils and volatile compounds [28,29].…”

Section: Discussionmentioning

confidence: 97%

Preparation, Characterization and Stability Study of Eugenol-Loaded Eudragit RS100 Nanocapsules for Dental Sensitivity Reduction

Vilela,

Ferreira,

Biscaia

et al. 2023

Braz. arch. biol. technol.

Self Cite

View full text Add to dashboard Cite

Eugenol is a phenolic compound with numerous biological activities. It is widely used in dentistry to treat toothache and pulpitis. In particular, eugenol may be used for tooth whitening procedures to minimize dental sensitivity in patients. However, eugenol has some disadvantages such as its volatility, its photosensitivity, and immediate effect, which can be avoided by using pharmaceutical nanotechnology. The HIGHLIGHTS• Eugenol-loaded Eudragit RS100 nanocapsules were suitably obtained and characterized.• A simple and fast UPLC/MS-MS method for determining eugenol in Eudragit RS100 nanocapsules was developed and validated.• Eugenol-loaded Eudragit RS100 nanocapsules showed physical stability after 60 days of preparation.• Eugenol-loaded Eudragit RS100 nanocapsules may be further used for reducing dental sensitivity.

show abstract

“…The encapsulation efficiency of TAC-loaded PCL nanocapsules was 99.39% [22]. This formulation (NC-1) was stable for 60 days [27].…”

Section: Preparation Of Ncsmentioning

confidence: 94%

Characterization and In Vitro and In Vivo Evaluation of Tacrolimus-Loaded Poly(ε-Caprolactone) Nanocapsules for the Management of Atopic Dermatitis

et al. 2021

Self Cite

View full text Add to dashboard Cite

Background: Tacrolimus (TAC) is a drug of natural origin used in conventional topical dosage forms to control atopic dermatitis. However, direct application of the drug often causes adverse side effects in some patients. Hence, drug nanoencapsulation could be used as an improved novel therapy to mitigate the adverse effects and enhance bioavailability of the drug. Methods: Physicochemical properties, in vitro drug release experiments, and in vivo anti-inflammatory activity studies were performed. Results: TAC-loaded nanocapsules were successfully prepared by the interfacial deposition of preformed polymer using poly(ε-caprolactone) (PCL). The nanoparticulate systems presented a spherical shape with a smooth and regular surface, adequate diameter (226 to 250 nm), polydispersity index below 0.3, and suitable electrical stability (−38 to −42 mV). X-ray diffraction confirmed that the encapsulation method provided mainly the drug molecular dispersion in the nanocapsule oily core. Fourier-transform infrared spectra suggested that nanoencapsulation did not result in chemical bonds between drug and polymer. In vitro drug dissolution experiments showed a controlled release with a slight initial burst. The release kinetics showed zero-order kinetics. As per the Korsmeyer–Peppas model, anomalous transport features were observed. TAC-loaded PCL nanocapsules exhibited excellent anti-inflammatory activity when compared to the free drug. Conclusions: TAC-loaded PCL nanocapsules can be suitably used as a novel nano-based dosage form to control atopic dermatitis.

show abstract

Stability testing of tacrolimus-loaded poly(ԑ-caprolactone) nanoparticles by physicochemical assays and Raman spectroscopy

Cited by 8 publications

References 31 publications

Simvastatin-Loaded Nanocapsules Reduce TNF-Α Expression in Rat Peritoneum After Infusion of Peritoneal Dialysis Solution

Simvastatin-Loaded Nanocapsules Reduce TNF-Α Expression in Rat Peritoneum After Infusion of Peritoneal Dialysis Solution

Preparation, Characterization and Stability Study of Eugenol-Loaded Eudragit RS100 Nanocapsules for Dental Sensitivity Reduction

Characterization and In Vitro and In Vivo Evaluation of Tacrolimus-Loaded Poly(ε-Caprolactone) Nanocapsules for the Management of Atopic Dermatitis

Contact Info

Product

Resources

About